STOK · Stoke Therapeutics Inc
United States · RS rating 40 · As of 2026-11-03
| Price | 26.99 USD |
|---|---|
| 1-day change | +1.9% |
| RS rating (overall / 1M / 3M / 12M) | 40 / 75 / 37 / 43 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 28 / 8 / 14 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -17.7% |
| Sales growth Q/Q | -86.8% |
| Distance from 52-week high | +29.6% |
| Market cap (USD) | $2.1B |